ADC Therapeutics (ADCT) Intangibles (2019 - 2023)
ADC Therapeutics (ADCT) posted Intangibles of $12.4 million for Q3 2023, down 8.7% sequentially from $13.5 million in Q2 2023, and down 15.34% YoY from $14.6 million in Q3 2022.
ADC Therapeutics (ADCT) Intangibles (2019 - 2023) Analysis & Trends
ADC Therapeutics has reported Intangibles for 5 years, with the latest figure at $12.4 million in Q3 2023.
- Quarterly Intangibles fell 15.34% year-over-year to $12.4 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $12.4 million (down 15.34% YoY) and the FY2022 annual result came in at $14.4 million, down 3.26% from the prior year.
- Intangibles declined to $12.4 million in Q3 2023 per ADCT's latest filing, from $13.5 million in the prior quarter.
- Over five years, Intangibles peaked at $14.8 million in Q4 2021 and troughed at $8.8 million in Q2 2020.
- A 5-year average of $12.4 million and a median of $13.3 million in 2021 frame the typical range for Intangibles.
- The sharpest annual moves came in 2022 and 2023: Intangibles jumped 36.5% in 2022, then slipped 15.34% in 2023.
- Over 5 years, Intangibles stood at $9.4 million in 2019, then advanced by 20.75% to $11.3 million in 2020, then soared by 31.22% to $14.8 million in 2021, then decreased by 3.26% to $14.4 million in 2022, then slipped by 13.94% to $12.4 million in 2023.
- According to Business Quant data, Intangibles over the past three periods registered $12.4 million, $13.5 million, and $13.6 million for Q3 2023, Q2 2023, and Q1 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | ADC Therapeutics | 154.55 Mn | -64.56 Mn | 17.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 12.36 Mn |
| Jun 30, 2023 | 13.54 Mn |
| Mar 31, 2023 | 13.59 Mn |
| Dec 31, 2022 | 14.36 Mn |
| Sep 30, 2022 | 14.60 Mn |
| Jun 30, 2022 | 14.58 Mn |
| Mar 31, 2022 | 13.85 Mn |
| Dec 31, 2021 | 14.84 Mn |
| Sep 30, 2021 | 13.32 Mn |
| Jun 30, 2021 | 12.01 Mn |
| Mar 31, 2021 | 10.15 Mn |
| Dec 31, 2020 | 11.31 Mn |
| Sep 30, 2020 | 9.81 Mn |
| Jun 30, 2020 | 8.82 Mn |
| Dec 31, 2019 | 9.37 Mn |